This is preserved historical wording.
It is no longer the current profile. Read the canonical profile and its correction notice.
It is no longer the current profile. Read the canonical profile and its correction notice.
What this version reported
FDA's emideltide briefing describes evidence and safety questions presented to the advisory committee. Committee recommendations are nonbinding, and FDA says its final determination will follow completion of the committee process and relevant reviews.↗↗
Sources for this version
- 1FDA briefing document for emideltide (DSIP) (free base) and emideltide acetate ↗
U.S. Food and Drug Administration · Official source · Source checked July 29, 2026
- 2July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting ↗
U.S. Food and Drug Administration · Official source · Source checked July 29, 2026